CVE:SUGR

SugarBud Craft Growers Competitors

C$0.06
+0.01 (+10.00 %)
(As of 04/19/2021 11:16 AM ET)
Add
Compare
Today's Range
C$0.05
Now: C$0.06
C$0.06
50-Day Range
C$0.05
MA: C$0.06
C$0.09
52-Week Range
C$0.03
Now: C$0.06
C$0.10
Volume454,807 shs
Average Volume2.71 million shs
Market CapitalizationC$29.63 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

SugarBud Craft Growers (CVE:SUGR) Vs. MDP, VIR, ZOM, CPH, IN, and NDVA

Should you be buying SUGR stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to SugarBud Craft Growers, including Medexus Pharmaceuticals (MDP), Viridium Pacific Group (VIR), Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM), Cipher Pharmaceuticals (CPH), InMed Pharmaceuticals (IN), and Indiva (NDVA).

Medexus Pharmaceuticals (CVE:MDP) and SugarBud Craft Growers (CVE:SUGR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Medexus Pharmaceuticals and SugarBud Craft Growers' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medexus PharmaceuticalsC$108.29 million1.26C$-34,573,801.00C($1.81)-3.95
SugarBud Craft GrowersC$66,906.00442.87C$-962,178,924.00C($1.79)-0.03

Medexus Pharmaceuticals has higher revenue and earnings than SugarBud Craft Growers. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than SugarBud Craft Growers, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Medexus Pharmaceuticals and SugarBud Craft Growers, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medexus Pharmaceuticals00203.00
SugarBud Craft Growers0000N/A

Profitability

This table compares Medexus Pharmaceuticals and SugarBud Craft Growers' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medexus PharmaceuticalsN/AN/AN/A
SugarBud Craft GrowersN/AN/AN/A

Viridium Pacific Group (CVE:VIR) and SugarBud Craft Growers (CVE:SUGR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.

Earnings and Valuation

This table compares Viridium Pacific Group and SugarBud Craft Growers' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridium Pacific GroupC$1.09 million34.46C$-12,637,824.00C($0.13)-2.97
SugarBud Craft GrowersC$66,906.00442.87C$-962,178,924.00C($1.79)-0.03

Viridium Pacific Group has higher revenue and earnings than SugarBud Craft Growers. Viridium Pacific Group is trading at a lower price-to-earnings ratio than SugarBud Craft Growers, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Viridium Pacific Group and SugarBud Craft Growers, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viridium Pacific Group0000N/A
SugarBud Craft Growers0000N/A

Profitability

This table compares Viridium Pacific Group and SugarBud Craft Growers' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viridium Pacific GroupN/AN/AN/A
SugarBud Craft GrowersN/AN/AN/A

Summary

Viridium Pacific Group beats SugarBud Craft Growers on 3 of the 5 factors compared between the two stocks.

Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM) and SugarBud Craft Growers (CVE:SUGR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Zomedica Pharmaceuticals Corp. (ZOM.V) and SugarBud Craft Growers, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zomedica Pharmaceuticals Corp. (ZOM.V)0000N/A
SugarBud Craft Growers0000N/A

Profitability

This table compares Zomedica Pharmaceuticals Corp. (ZOM.V) and SugarBud Craft Growers' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zomedica Pharmaceuticals Corp. (ZOM.V)N/AN/AN/A
SugarBud Craft GrowersN/AN/AN/A

Earnings & Valuation

This table compares Zomedica Pharmaceuticals Corp. (ZOM.V) and SugarBud Craft Growers' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zomedica Pharmaceuticals Corp. (ZOM.V)N/AN/AN/AC($0.11)-2.61
SugarBud Craft GrowersC$66,906.00442.87C$-962,178,924.00C($1.79)-0.03

Zomedica Pharmaceuticals Corp. (ZOM.V) has higher earnings, but lower revenue than SugarBud Craft Growers. Zomedica Pharmaceuticals Corp. (ZOM.V) is trading at a lower price-to-earnings ratio than SugarBud Craft Growers, indicating that it is currently the more affordable of the two stocks.

Summary

SugarBud Craft Growers beats Zomedica Pharmaceuticals Corp. (ZOM.V) on 2 of the 3 factors compared between the two stocks.

SugarBud Craft Growers (CVE:SUGR) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Valuation and Earnings

This table compares SugarBud Craft Growers and Cipher Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SugarBud Craft GrowersC$66,906.00442.87C$-962,178,924.00C($1.79)-0.03
Cipher PharmaceuticalsC$21.61 million1.66C$5.64 millionC$0.216.36

Cipher Pharmaceuticals has higher revenue and earnings than SugarBud Craft Growers. SugarBud Craft Growers is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for SugarBud Craft Growers and Cipher Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SugarBud Craft Growers0000N/A
Cipher Pharmaceuticals01102.50

Profitability

This table compares SugarBud Craft Growers and Cipher Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SugarBud Craft GrowersN/AN/AN/A
Cipher PharmaceuticalsN/AN/AN/A

Summary

Cipher Pharmaceuticals beats SugarBud Craft Growers on 5 of the 6 factors compared between the two stocks.

SugarBud Craft Growers (CVE:SUGR) and InMed Pharmaceuticals (TSE:IN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.

Profitability

This table compares SugarBud Craft Growers and InMed Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SugarBud Craft GrowersN/AN/AN/A
InMed PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for SugarBud Craft Growers and InMed Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SugarBud Craft Growers0000N/A
InMed Pharmaceuticals0000N/A

Valuation & Earnings

This table compares SugarBud Craft Growers and InMed Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SugarBud Craft GrowersC$66,906.00442.87C$-962,178,924.00C($1.79)-0.03
InMed PharmaceuticalsN/AN/AN/AC($1.81)-1.94

InMed Pharmaceuticals has lower revenue, but higher earnings than SugarBud Craft Growers. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than SugarBud Craft Growers, indicating that it is currently the more affordable of the two stocks.

Summary

SugarBud Craft Growers beats InMed Pharmaceuticals on 3 of the 3 factors compared between the two stocks.

SugarBud Craft Growers (CVE:SUGR) and Indiva (CVE:NDVA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings.

Profitability

This table compares SugarBud Craft Growers and Indiva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SugarBud Craft GrowersN/AN/AN/A
IndivaN/AN/AN/A

Valuation and Earnings

This table compares SugarBud Craft Growers and Indiva's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SugarBud Craft GrowersC$66,906.00442.87C$-962,178,924.00C($1.79)-0.03
IndivaC$7.92 million7.81C$-17,223,168.00C($0.13)-3.59

Indiva has higher revenue and earnings than SugarBud Craft Growers. Indiva is trading at a lower price-to-earnings ratio than SugarBud Craft Growers, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for SugarBud Craft Growers and Indiva, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SugarBud Craft Growers0000N/A
Indiva00103.00

Indiva has a consensus target price of C$0.63, suggesting a potential upside of 36.96%. Given Indiva's higher possible upside, analysts plainly believe Indiva is more favorable than SugarBud Craft Growers.

Summary

Indiva beats SugarBud Craft Growers on 5 of the 7 factors compared between the two stocks.


SugarBud Craft Growers Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
MDP
Medexus Pharmaceuticals
0.6$7.15+2.1%C$38.66 millionC$108.29 million-3.95
VIR
Viridium Pacific Group
0.7$0.38+5.3%C$37.54 millionC$1.09 million-2.97Gap Down
ZOM
Zomedica Pharmaceuticals Corp. (ZOM.V)
0.6$0.29+7.0%C$36.73 millionN/A-2.61Gap Up
Cipher Pharmaceuticals logo
CPH
Cipher Pharmaceuticals
0.7$1.33+0.0%C$35.87 millionC$21.61 million6.36
IN
InMed Pharmaceuticals
0.6$3.52+4.8%C$29.71 millionN/A-1.94
NDVA
Indiva
1.3$0.46+1.1%C$27.54 millionC$7.92 million-3.59
Harvest One Cannabis logo
HVT
Harvest One Cannabis
0.4$0.11+0.0%C$21.51 millionC$8.50 million-0.31Gap Down
EVE
Eve & Co Incorporated
1.0$0.35+4.3%C$21.32 millionC$2.84 million-1.10Gap Down
NU
NeutriSci International
0.5$0.19+2.7%C$8.65 millionC$69,626.00-14.23Gap Up
AQS
Aequus Pharmaceuticals
0.5$0.20+5.0%C$6.03 millionC$2.28 million-9.09News Coverage
Gap Down
LBL
Lattice Biologics
0.5$0.05+0.0%C$4.67 millionC$2.24 million-2.37
THCX
(THCX.V)
0.6$5.30+6.2%C$0.00N/A0.00
GLH
31444
0.4N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
ACG
438280
0.6N/AN/AC$0.00N/A0.00Gap Down
HC
815446
0.5N/AN/A$0.00N/A0.00Gap Down
BIO
Bio-Rad Laboratories
0.5N/AN/A$0.00N/A0.00High Trading Volume
BBM
Blueberries Medical
0.6N/AN/A$0.00N/A0.00High Trading Volume
LOVE
Cannara Biotech
0.7N/AN/A$0.00N/A0.00High Trading Volume
CALI
China Auto Logistics
1.3N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
MJ
ETFMG Alternative Harvest ETF
0.5N/AN/A$0.00N/A0.00News Coverage
Gap Down
BOSS
Global X Founder-Run Companies ETF
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
LHS
Liberty Health Sciences
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
Gap Up
LIB
Liberty Leaf
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Down
MMEN
Medmen Enterprises
0.6N/AN/A$0.00N/A0.00High Trading Volume
RQB
Ravenquest Biomed
0.6N/AN/A$0.00N/A0.00High Trading Volume
TGIF
SoFi Weekly Income ETF
0.6N/AN/A$0.00N/A0.00High Trading Volume
Valeant Pharmaceuticals International logo
VRX
Valeant Pharmaceuticals International
0.5$30.80+3.4%C$0.00N/A0.00
VRT
Vertiv
0.5N/AN/A$0.00N/A0.00Gap Down
This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.